CORT vs SUPN

For growth investors, Corcept Therapeutics Incorporated (CORT) is the stronger pick with 12.

8% revenue growth year-over-year, versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). Corcept Therapeutics Incorporated (CORT) offers the better valuation at 63. 6x trailing P/E (138. 9x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Supernus Pharmaceuticals, Inc.

is actually cheaper at 23. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +140.

2%, compared to +75. 7% for Supernus Pharmaceuticals, Inc. (SUPN). Over 10 years, the gap is even starker: CORT returned +991. 0% versus SUPN's +240. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Supernus Pharmaceuticals, Inc.

(SUPN) is the lower-risk stock at 0. 78β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 127% more volatile than SUPN relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 4% for Supernus Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Corcept Therapeutics Incorporated (CORT) is pulling ahead at 12.

8% versus 8. 6% for Supernus Pharmaceuticals, Inc. (SUPN). On earnings-per-share growth, the picture is similar: Corcept Therapeutics Incorporated grew EPS -33. 3% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, CORT leads at 23. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.

1% net margin versus -5. 4% for Supernus Pharmaceuticals, Inc. — meaning it keeps 13. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CORT leads at 5. 9% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — CORT leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Supernus Pharmaceuticals, Inc.

(SUPN) trades at 23. 7x forward P/E versus 138. 9x for Corcept Therapeutics Incorporated — 115. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 37. 4% to $71. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Supernus Pharmaceuticals, Inc.

(SUPN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78), +240. 3% 10Y return). Corcept Therapeutics Incorporated (CORT) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SUPN: +240. 3%, CORT: +991. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.